Our mission is to create, develop and protect new products and technologies that have the potential to significantly improve patients' lives.
Innovation
Our products are designed to improve modern day practice.
UP TO DATE PRESS RELEASES
See Below
ANTIVIRALS
Woman-owned Palisades Therapeutics in collaboration with the Veterans Medical Research Foundation is granted FDA clearance to begin Phase II/III COVID-outpatient oral therapeutic study that targets >80% of patients
PALISADES THERAPEUTICS ANNOUNCES A NEWLY PATENTED NOVEL APPROACH THAT COULD BE KEY TO STOPPING COVID AND OTHER VIRUSES
A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection
Palisades Therapeutics’ Proprietary Dual Action Compound Reduces COVID-19 Viral Entry and Inflammatory Responses
Palisades Therapeutics PT150 for treatment of “long haul COVID” neuro-psychiatric conditions
Palisades Therapeutics pioneers new therapeutic for rare disease Parechovirus.
PT150 for treatment of “Long Haul COVID” featured poster at the neuroscience clinical-translational research symposium.
NEURODEGENERATION
Palisades Therapeutics Drug Platform Demonstrates Reduction in Neuroinflammation Across Three Species
Palisades Therapeutics’ Clinical Stage Drug PT150 Granted Patent for Parkinson’s Disease and Multiple Sclerosis
ONCOLOGY
Pan-cancer analysis to identify a novel class of glucocorticoid and androgen receptor antagonists with potent anti-tumor activity.
Palisades Therapeutics Targets the IHOP Protein as a Biomarker to Detect Pancreatic Cancer and Enable PT Therapeutic
Palisades Therapeutics Announces New Anti-Cancer Drug-PT162, a p53-Reactivating Cell Cycle Checkpoint Inhibitor
AGRICULTURE
Proprietary Dual Action Compound Could Save the Citrus Industry from Citrus Greening Plague
Eradicating Citrus Greening By Dual Action Targeting of Liberibacter asiaticus and Diaphorina citri
ADDICTIONS
Pill to pill communication provides prescription compliance, drug delivery, safety and sampling of gut bacteria.
The current study investigated whether the stress hormone receptor antagonist, PT150, would block the rewarding properties of ethanol via the glucocorticoid receptor system and attenuate other ethanol-induced effects.
"The most brilliant ideas are the ones that make you consider why we haven't always done it this way."
About Us
BUSINESS MODEL
We out-license or sell our products and intellectual property to third parties for global commercialization. Our companies have a unique paradigm. We consist of leading scientists, physicians, clinicians, lawyers and professionals working together without salary to change the world.
This site was created to keep industry insiders aware of our progress in the areas of Diagnostics, Therapeutics and Devices.
________
Poster featured at the 2021 California Citrus Conference
Combined Antibiotic And Glucocorticoid Antagonism As A Method For Disrupting The Citrus Greening Life Cycle
Anthony R Arment, PhD1, Eric W Triplett, PhD2, Cody Artzner2, Neil D Theise, MD3
1 Central State University, 2University of Florida, 3Palisades Therapeutics
Our Innovations
Why Choose Us!
Reliable Team of Experts and Innovators
Every product is backed by our incredible group of industry experts consisting of physicians, scientists and much more.
Fully Covered Intellectual Property
We have gathered an incredible team of intellectual property lawyers to help fully protect our products all over the world.
Diverse Portfolio of Programs
Our team designs and looks to generate compelling proof of concept data for each program to facilitate global commercialization by a partner/acquirer.
Our Collaborators
